Evaluating the association between ccr5delta32 polymorphism (Rs333) and the risk of breast cancer in a cohort of Iranian population

Amir Tajbakhsh; Zahra Farjami; Abolfazl Nesaei-Bajestani; Fahimeh Afzaljavan; Mahdi Rivandi; Atefeh Moezzi; Soheila Abedini; Mahla Asghari; Mohammad Mahdi Kooshyar; Fatemeh Homaei Shandiz; Alireza Pasdar

Evaluating the association between ccr5delta32 polymorphism (Rs333) and the risk of breast cancer in a cohort of Iranian population

Amir Tajbakhsh, Zahra Farjami, Abolfazl Nesaei-Bajestani^* (Corresponding Author), Fahimeh Afzaljavan, Mahdi Rivandi, Atefeh Moezzi, Soheila Abedini, Mahla Asghari, Mohammad Mahdi Kooshyar, Fatemeh Homaei Shandiz, Alireza Pasdar^* (Corresponding Author)

^*Corresponding author for this work

Applied Medicine

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

4 Downloads (Pure)

Abstract

Background: CC chemokine receptor 5 (CCR5) is introduced as an immune response modulator. The activi-ty of CCR5 influences breast tumour development in a p53-dependent manner. This study aimed to investigate the frequency of CCR5delta32 and its association with the risk of breast cancer in 1038 blood samples in North East of Iran. Methods: In this case-control study, we genotyped 570 control samples and 468 breast cancer patients by a gel electrophoresis-based gap-polymerase chain reaction (gap-PCR) method Mashhad, Iran. The data were analyzed using the SPSS software. Results: Of 570 controls included, 542 (95.09%) had CCR5delta32^{wild/wild (W/W)} genotype, 28 samples (4.91%) had CCR5delta32^{wild/deletion (W/D)} genotype and none of them were CCR5delta32^{deletion/deletion (D/D)} genotype (0%). While 428 samples of patients (91.45%) had CCR5delta32^W/W genotype, 40 samples (8.55%) had CCR5delta32 W/D and CCR5delta32^D/D homozygous was nil (0%) amongst cases. All samples were in the Hardy–Weinberg equilibrium (P>0.05). According to the allele frequency, D allele, as a risky allele, in the cases was more than the control samples (0.0427 vs 0.0245, respectively) (P=0.0206). Hence, W/D genotype may confer a risk effect (OR=1.77, CI: 1.09-2.90; P=0.0206) compared with WW genotype between case and control groups. Conclusion: There is a statistically significant association between CCR5W/D and breast cancer risk. CCR5 may be regarded as a target for the prevention of breast cancer in certain conditions such as interaction with p53 variants, which remains to be further investigated.

Original language	English
Pages (from-to)	583-591
Number of pages	9
Journal	Iranian Journal of Public Health
Volume	50
Issue number	3
Publication status	Published - 1 Mar 2021

Keywords

Breast carcinoma
CCR5D32
Immunogenetics
Metastasis
P53 pathway

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Tajbakhsh_etal_evaluating_the_association_VOR
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
Final published version, 1 MBLicence: CC BY-NC

Cite this

Evaluating the association between ccr5delta32 polymorphism (Rs333) and the risk of breast cancer in a cohort of Iranian population. / Tajbakhsh, Amir; Farjami, Zahra; Nesaei-Bajestani, Abolfazl (Corresponding Author) et al.

In: Iranian Journal of Public Health, Vol. 50, No. 3, 01.03.2021, p. 583-591.

Research output: Contribution to journal › Article › peer-review

@article{4f8b00dc111b4ad9a01f39d86de07f9b,

title = "Evaluating the association between ccr5delta32 polymorphism (Rs333) and the risk of breast cancer in a cohort of Iranian population",

abstract = "Background: CC chemokine receptor 5 (CCR5) is introduced as an immune response modulator. The activi-ty of CCR5 influences breast tumour development in a p53-dependent manner. This study aimed to investigate the frequency of CCR5delta32 and its association with the risk of breast cancer in 1038 blood samples in North East of Iran. Methods: In this case-control study, we genotyped 570 control samples and 468 breast cancer patients by a gel electrophoresis-based gap-polymerase chain reaction (gap-PCR) method Mashhad, Iran. The data were analyzed using the SPSS software. Results: Of 570 controls included, 542 (95.09%) had CCR5delta32wild/wild (W/W) genotype, 28 samples (4.91%) had CCR5delta32wild/deletion (W/D) genotype and none of them were CCR5delta32deletion/deletion (D/D) genotype (0%). While 428 samples of patients (91.45%) had CCR5delta32W/W genotype, 40 samples (8.55%) had CCR5delta32 W/D and CCR5delta32D/D homozygous was nil (0%) amongst cases. All samples were in the Hardy–Weinberg equilibrium (P>0.05). According to the allele frequency, D allele, as a risky allele, in the cases was more than the control samples (0.0427 vs 0.0245, respectively) (P=0.0206). Hence, W/D genotype may confer a risk effect (OR=1.77, CI: 1.09-2.90; P=0.0206) compared with WW genotype between case and control groups. Conclusion: There is a statistically significant association between CCR5W/D and breast cancer risk. CCR5 may be regarded as a target for the prevention of breast cancer in certain conditions such as interaction with p53 variants, which remains to be further investigated.",

keywords = "Breast carcinoma, CCR5D32, Immunogenetics, Metastasis, P53 pathway",

author = "Amir Tajbakhsh and Zahra Farjami and Abolfazl Nesaei-Bajestani and Fahimeh Afzaljavan and Mahdi Rivandi and Atefeh Moezzi and Soheila Abedini and Mahla Asghari and Kooshyar, {Mohammad Mahdi} and {Homaei Shandiz}, Fatemeh and Alireza Pasdar",

note = "Funding Information: This manuscript was supported by the Student Research Committee of Mashhad University of science (Grant Numbers: 951734 & 961689). ",

year = "2021",

month = mar,

day = "1",

language = "English",

volume = "50",

pages = "583--591",

journal = "Iranian Journal of Public Health",

issn = "2251-6085",

publisher = "Iranian Journal of Public Health",

number = "3",

}

TY - JOUR

T1 - Evaluating the association between ccr5delta32 polymorphism (Rs333) and the risk of breast cancer in a cohort of Iranian population

AU - Tajbakhsh, Amir

AU - Farjami, Zahra

AU - Nesaei-Bajestani, Abolfazl

AU - Afzaljavan, Fahimeh

AU - Rivandi, Mahdi

AU - Moezzi, Atefeh

AU - Abedini, Soheila

AU - Asghari, Mahla

AU - Kooshyar, Mohammad Mahdi

AU - Homaei Shandiz, Fatemeh

AU - Pasdar, Alireza

N1 - Funding Information: This manuscript was supported by the Student Research Committee of Mashhad University of science (Grant Numbers: 951734 & 961689).

PY - 2021/3/1

Y1 - 2021/3/1

N2 - Background: CC chemokine receptor 5 (CCR5) is introduced as an immune response modulator. The activi-ty of CCR5 influences breast tumour development in a p53-dependent manner. This study aimed to investigate the frequency of CCR5delta32 and its association with the risk of breast cancer in 1038 blood samples in North East of Iran. Methods: In this case-control study, we genotyped 570 control samples and 468 breast cancer patients by a gel electrophoresis-based gap-polymerase chain reaction (gap-PCR) method Mashhad, Iran. The data were analyzed using the SPSS software. Results: Of 570 controls included, 542 (95.09%) had CCR5delta32wild/wild (W/W) genotype, 28 samples (4.91%) had CCR5delta32wild/deletion (W/D) genotype and none of them were CCR5delta32deletion/deletion (D/D) genotype (0%). While 428 samples of patients (91.45%) had CCR5delta32W/W genotype, 40 samples (8.55%) had CCR5delta32 W/D and CCR5delta32D/D homozygous was nil (0%) amongst cases. All samples were in the Hardy–Weinberg equilibrium (P>0.05). According to the allele frequency, D allele, as a risky allele, in the cases was more than the control samples (0.0427 vs 0.0245, respectively) (P=0.0206). Hence, W/D genotype may confer a risk effect (OR=1.77, CI: 1.09-2.90; P=0.0206) compared with WW genotype between case and control groups. Conclusion: There is a statistically significant association between CCR5W/D and breast cancer risk. CCR5 may be regarded as a target for the prevention of breast cancer in certain conditions such as interaction with p53 variants, which remains to be further investigated.

AB - Background: CC chemokine receptor 5 (CCR5) is introduced as an immune response modulator. The activi-ty of CCR5 influences breast tumour development in a p53-dependent manner. This study aimed to investigate the frequency of CCR5delta32 and its association with the risk of breast cancer in 1038 blood samples in North East of Iran. Methods: In this case-control study, we genotyped 570 control samples and 468 breast cancer patients by a gel electrophoresis-based gap-polymerase chain reaction (gap-PCR) method Mashhad, Iran. The data were analyzed using the SPSS software. Results: Of 570 controls included, 542 (95.09%) had CCR5delta32wild/wild (W/W) genotype, 28 samples (4.91%) had CCR5delta32wild/deletion (W/D) genotype and none of them were CCR5delta32deletion/deletion (D/D) genotype (0%). While 428 samples of patients (91.45%) had CCR5delta32W/W genotype, 40 samples (8.55%) had CCR5delta32 W/D and CCR5delta32D/D homozygous was nil (0%) amongst cases. All samples were in the Hardy–Weinberg equilibrium (P>0.05). According to the allele frequency, D allele, as a risky allele, in the cases was more than the control samples (0.0427 vs 0.0245, respectively) (P=0.0206). Hence, W/D genotype may confer a risk effect (OR=1.77, CI: 1.09-2.90; P=0.0206) compared with WW genotype between case and control groups. Conclusion: There is a statistically significant association between CCR5W/D and breast cancer risk. CCR5 may be regarded as a target for the prevention of breast cancer in certain conditions such as interaction with p53 variants, which remains to be further investigated.

KW - Breast carcinoma

KW - CCR5D32

KW - Immunogenetics

KW - Metastasis

KW - P53 pathway

UR - https://iranjournals.nlai.ir/handle/123456789/784973

M3 - Article

AN - SCOPUS:85101525383

VL - 50

SP - 583

EP - 591

JO - Iranian Journal of Public Health

JF - Iranian Journal of Public Health

SN - 2251-6085

IS - 3

ER -

Evaluating the association between ccr5delta32 polymorphism (Rs333) and the risk of breast cancer in a cohort of Iranian population

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this